A 14-year-old girl with type 2 diabetes and BMI 30 has not achieved HbA1c targets after lifestyle changes. What is the most appropriate medicine to initiate as the next line of treatment?

A 14-year-old girl with type 2 diabetes and BMI 30 has not achieved HbA1c targets after lifestyle changes. What is the most appropriate medicine to initiate as the next line of treatment?

• A. Insulin
• B. Metformin
• C. Sulfonylurea
• D. GLP-1 receptor agonist

Answer: (B)

Metformin is the best next step for an adolescent with type 2 diabetes who hasn’t reached HbA1c targets after lifestyle changes because it specifically improves the underlying metabolic issues seen in youth with this condition: reduced hepatic glucose production and improved insulin sensitivity. This leads to lower fasting glucose and HbA1c. It also has a favorable safety profile in children, with a low risk of hypoglycemia when used alone, and it tends to be weight-neutral or even promote modest weight loss—an important consideration for someone with a BMI around 30. Starting with a low dose and titrating up with meals (for example, beginning around 500 mg once daily and increasing to the typical effective range) is common, and dosing is adjusted based on tolerance and kidney function. If HbA1c remains above target despite optimized metformin, additional therapies can be considered, such as GLP-1 receptor agonists or insulin, depending on the individual situation. Other options like sulfonylureas carry a higher risk of hypoglycemia and weight gain, and insulin is generally reserved for more severe hyperglycemia or when oral agents are insufficient, making them less suitable as the initial step in this scenario.

Metformin is the best next step for an adolescent with type 2 diabetes who hasn’t reached HbA1c targets after lifestyle changes because it specifically improves the underlying metabolic issues seen in youth with this condition: reduced hepatic glucose production and improved insulin sensitivity. This leads to lower fasting glucose and HbA1c. It also has a favorable safety profile in children, with a low risk of hypoglycemia when used alone, and it tends to be weight-neutral or even promote modest weight loss—an important consideration for someone with a BMI around 30.

Starting with a low dose and titrating up with meals (for example, beginning around 500 mg once daily and increasing to the typical effective range) is common, and dosing is adjusted based on tolerance and kidney function. If HbA1c remains above target despite optimized metformin, additional therapies can be considered, such as GLP-1 receptor agonists or insulin, depending on the individual situation. Other options like sulfonylureas carry a higher risk of hypoglycemia and weight gain, and insulin is generally reserved for more severe hyperglycemia or when oral agents are insufficient, making them less suitable as the initial step in this scenario.